Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. CStone Pharmaceuticals
  6. Summary
    2616   KYG2588M1006

CSTONE PHARMACEUTICALS

(2616)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
9.88 10.26 10.08 9.78 9.85 Last
1627500 2764000 2082096 1582701 1208500 Volume
+0.30% +3.85% -1.75% -2.98% +0.72% Change
Estimated financial data (e)
Sales 2021 271 M 42,4 M 42,4 M
Net income 2021 -1 829 M -287 M -287 M
Net cash position 2021 1 635 M 256 M 256 M
P/E ratio 2021 -5,90x
Yield 2021 -
Sales 2022 1 230 M 193 M 193 M
Net income 2022 -1 551 M -243 M -243 M
Net cash position 2022 1 761 M 276 M 276 M
P/E ratio 2022 -6,49x
Yield 2022 -
Capitalization 9 407 M 1 473 M 1 474 M
EV / Sales 2021 28,7x
EV / Sales 2022 6,21x
Nbr of Employees 573
Free-Float 75,2%
More Financials
Company
CStone Pharmaceuticals is a China-based investment holding company. Through its subsidiaries, the Company is primarily engaged in development, manufacturing and sales of biopharmaceutical products. Its main products include immuno-oncology drugs and molecularly targeted drugs. The Company conducts its businesses mainly in domestic market. 
More about the company
Ratings of CStone Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about CSTONE PHARMACEUTICALS
10/20CStone Pharmaceuticals Received China NMPA IND Acceptance for lorlatinib in Chinese Pat..
CI
10/19CSTONE PHARMACEUTICALS : Chinese Regulators OK CStone's Investigational New Drug Applicati..
MT
10/08CSTONE PHARMACEUTICALS : presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-..
AQ
10/07CSTONE PHARMACEUTICALS : Achieves Potential Antitumor Activity From Preclinical Antibody T..
MT
10/01CStone Presents Arrow Study Data for GAVRETO« (Pralsetinib) in Chinese Patients with Re..
CI
09/28CSTONE PHARMACEUTICALS : announced that the research data of CS5001 (ROR1 ADC) has been se..
AQ
09/21CSTONE PHARMACEUTICALS : Pharma Presents Cancer Drug's Bridging Study Data at Oncology Con..
MT
09/20CSTONE PHARMACEUTICALS : presents preliminary results from a phase Ib study of the anti-CT..
AQ
09/20CStone Pharmaceuticals Presents Clinical Data from the China Registrational Bridging St..
CI
09/19CSTONE PHARMACEUTICALS' : Investigational Cancer Treatment Shows Potential in Phase 1b Tri..
MT
09/18Cstone Presents Preliminary Results from Phase Ib Study of the Anti-Ctla-4 Monoclonal A..
CI
09/17EQRx and its Partner CStone Pharmaceuticals Announce Presentation of Phase 3 Data Demon..
CI
09/17CStone Pharmaceuticals Will Present Registrational Clinical Study Data of Sugemalimab i..
CI
09/16CSTONE PHARMACEUTICALS : to Present Phase 3 Trial Data of Non-Small Cell Lung Cancer Treat..
MT
09/15CSTONE PHARMACEUTICALS : received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-..
AQ
More news
News in other languages on CSTONE PHARMACEUTICALS
10/19Les autorités réglementaires chinoises approuvent la demande d'autorisation de mise sur..
10/07CStone Pharmaceuticals obtient une activité antitumorale potentielle lors d'un essai pr..
09/21CStone Pharma présente les données de l'étude de transition d'un médicament anticancére..
09/19Le traitement expérimental du cancer de CStone Pharmaceuticals montre son potentiel dan..
09/16CStone Pharmaceuticals présente les résultats d'un essai de phase 3 sur un traitement c..
More news
Chart CSTONE PHARMACEUTICALS
Duration : Period :
CStone Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSTONE PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 8,09 CNY
Average target price 14,73 CNY
Spread / Average Target 82,1%
EPS Revisions
Managers and Directors
Ning Jun Jiang Chairman & Chief Executive Officer
Jian Xin Yang Chief Medical Officer & Senior Vice President
Xin Zhong Wang Chief Scientific Officer & Senior Vice President
Ting Yuk Wu Independent Non-Executive Director
Hong Bin Sun Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CSTONE PHARMACEUTICALS-2.28%1 473
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610